Back to search
Treatment of Viral Hemorrhagic Fevers With Intravenous Ribavirin in Military Treatment Facilities
NCT00992693
PHASE2INTERVENTIONAL
U.S. Army Medical Research and Development Command
0Started 2009-09 · Completed 2019-12-17
Status: Withdrawn (as of 12-23-2025)
Conditions
Crimean-Congo Hemorrhagic FeverLassa Fever
Interventions
Linked Papers (from SciSciNet-V2)
Total Papers0
Background
0Result
0Derived
0Unknown
0Brief Summary
This is a Phase 2 study of the safety and efficacy of Intravenous (IV) Ribavirin in treating patients presenting with a probable or suspected case of viral hemorrhagic fever (either Crimean Congo or Lassa Fever) at a military medical treatment hospital. All patients will be treated with a 10 day course of IV Ribavirin if they meet all the inclusion and none of the exclusion criteria.
No papers linked to this trial in SciSciNet
Visit ClinicalTrials.gov for more information about this study